Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC17A6-DT (SLC17A6 divergent transcript) is a long non-coding RNA transcribed from a locus adjacent to the SLC17A6 gene, which encodes vesicular glutamate transporter 2. Divergent lncRNAs are a subclass of long non-coding RNAs that arise by transcription from promoters near protein-coding genes, often in an antisense or bidirectional manner. These lncRNAs can regulate the expression of nearby genes through chromatin remodeling, transcriptional interference, or recruitment of epigenetic regulators, as demonstrated by molecular analogs like GATA3-AS1[2]. However, SLC17A6-DT itself does not have experimentally validated biological function, targetability, or disease relevance. The existence, sequence, and regulatory impact of SLC17A6-DT as a distinct entity remain putative, requiring further validation. It is not recognized as a therapeutic target, receptor, enzyme, or transporter[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SLC17A6 divergent transcript (SLC17A6-DT).